Newsroom

Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO

This report provides an evidence-based review of current treatments for managing dry eye disease (DED) and highlights support for TearCare based on strong clinical data MENLO PARK, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional […]

read more +
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

PDF Version MENLO PARK, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference […]

read more +
Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the second quarter ended June 30, 2025, and raised its revenue […]

read more +
Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

PDF Version Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes Research MENLO PARK, Calif., July 30, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced the […]

read more +
Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease

PDF Version Mean signs and symptoms for participants in Stage 3 of the SAHARA trial remained statistically significantly better than study baseline at all time points measured up to 24 months MENLO PARK, Calif., July 29, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused […]

read more +
Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025

PDF Version MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced it will report financial results for the second quarter ended June 30, 2025, […]

read more +
Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th

MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at the Stifel 2025 Virtual Ophthalmology Forum. Sight Sciences’ management is […]

read more +
Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

May 8, 2025 PDF Version MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the first quarter ended March 31, 2025, reaffirms revenue guidance for […]

read more +